Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

The ARTESIA trial demonstrates that Apixaban effectively reduces the risk of stroke or systemic embolism in patients with subclinical atrial fibrillation. Despite the increased risk of major bleeding, the severity of prevented stroke events outweighs the severity of bleeding events caused by the drug. This could potentially change the approach to managing subclinical atrial fibrillation in patients at high risk of stroke.

Original Article

Join this channel to get access to perks:

DISCLAIMER
⚠️ For Healthcare Practitioners: This content is provided only for medical education. Although the authors have made every effort to provide the most up-to-date, evidence-based medical information, this content should not necessarily be considered the standard of care. It may not reflect individual practices in other geographic locations. It should be considered in the context of other medical educational resources.
⚠️ For the Public: This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. You should contact your own physician or other qualified healthcare providers with any questions you may have regarding your medical condition. Do not disregard professional medical advice or delay seeking it based on information from this content. Relying on information provided in this content is done at your own risk. In a medical emergency, contact your physician or call 9-1-1 immediately.

[Clandestineclementine]

This is a great finding for people with AF who are constantly at risk of Stroke

[fastmohawk]

i know it's out of scope, but i would like to get more details on possible different settings of these two RCTs which may account for these east-west results